IFP Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $48.2K | Sell |
1,533
-1,430
| -48% | -$45K | ﹤0.01% | 2418 |
|
|
2026
Q2 | $93.1K | Buy |
2,963
+963
| +48% | +$28.4K | ﹤0.01% | 2029 |
|
|
2026
Q1 | $49.5K | Buy |
2,000
+1,052
| +111% | +$25.1K | ﹤0.01% | 2251 |
|
|
2025
Q4 | $22.1K | Buy |
948
+945
| +31,500% | +$21.1K | ﹤0.01% | 2682 |
|
|
2025
Q3 | $59 | Sell |
3
-101
| -97% | -$2.08K | ﹤0.01% | 4631 |
|
|
2025
Q2 | $2.26K | Buy |
104
+81
| +352% | +$1.91K | ﹤0.01% | 3842 |
|
|
2025
Q1 | $558 | Hold |
23
| – | – | ﹤0.01% | 3438 |
|
|
2024
Q4 | $480 | Buy |
+23
| New | +$494 | ﹤0.01% | 3427 |
|
|
2023
Q3 | – | Sell |
-670
| Closed | -$9K | – | 3344 |
|
|
2023
Q2 | $9K | Buy |
670
+170
| +34% | +$2.45K | ﹤0.01% | 2336 |
|
|
2023
Q1 | $1.82K | Sell |
500
-1,523
| -75% | -$25.1K | ﹤0.01% | 2927 |
|
|
2022
Q4 | $12K | Sell |
2,023
-376
| -16% | -$5.79K | ﹤0.01% | 3253 |
|
|
2022
Q3 | $9K | Hold |
2,399
| – | – | ﹤0.01% | 3698 |
|
|
2022
Q2 | $9K | Hold |
2,399
| – | – | ﹤0.01% | 3454 |
|
|
2022
Q1 | $9K | Buy |
+2,399
| New | +$17K | ﹤0.01% | 3454 |
|
|
2019
Q4 | – | Sell |
-1,324
| Closed | -$6.19K | – | 2874 |
|
|
2019
Q3 | $7K | Buy |
+1,324
| New | +$7.05K | ﹤0.01% | 2209 |
|
|
2017
Q4 | – | Sell |
-1,000
| Closed | -$3K | – | 3841 |
|
|
2017
Q3 | $3K | Hold |
1,000
| – | – | ﹤0.01% | 3597 |
|
|
2017
Q2 | $3K | Hold |
1,000
| – | – | ﹤0.01% | 3591 |
|
|
2017
Q1 | $2K | Hold |
1,000
| – | – | ﹤0.01% | 3632 |
|
|
2016
Q4 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 3759 |
|
|
2016
Q3 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 3699 |
|
|
2016
Q2 | $1K | Buy |
+1,000
| New | +$806 | ﹤0.01% | 3591 |
|
IFP Advisors's CPRX Position: Q3 2026 in Review
IFP Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 48% in Q3 2026, selling an estimated $45K and leaving 1,533 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2418.
IFP Advisors first reported a position in CPRX in Q2 2016 and has held it in 21 quarters since. The position peaked at $93.1K in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.
- IFP Advisors held 1,533 shares of Catalyst Pharmaceutical worth $48.2K as of Q3 2026.
- IFP Advisors sold 1,430 Catalyst Pharmaceutical shares in Q3 2026, an estimated $45K.
- Catalyst Pharmaceutical made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #2418 holding.
- IFP Advisors first reported a position in Catalyst Pharmaceutical in Q2 2016 and has held it in 21 quarters since.
- IFP Advisors's Catalyst Pharmaceutical position peaked at $93.1K in Q2 2026.
- 1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.